

# Quantify the mesenchymal population and the osteogenic differentiation of bone marrow cells

Published: 07-04-2014

Last updated: 20-04-2024

To quantify the MSC population of concentrated bone marrow aspirate and examine their differential potentials and the variation among patients and examine similarities and differences with the current literature.

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Will not start
<b>Health condition type</b>	Joint disorders
<b>Study type</b>	Observational invasive

## Summary

### ID

NL-OMON41207

### Source

ToetsingOnline

### Brief title

bone marrow compensation

### Condition

- Joint disorders

### Synonym

orthopedic differentiation of stem cells

### Research involving

Human

### Sponsors and support

**Primary sponsor:** Academisch Medisch Centrum

**Source(s) of monetary or material Support:** Marti-Keuning Eckhart Stichting

## Intervention

**Keyword:** bone marrow, mesenchymal, osteoprogenitor, stem cell

## Outcome measures

### Primary outcome

Average number of stem cells available in a bone marrow aspirate and the different cell types in %.

### Secondary outcome

Number of stem cells with bone or vascular generating potentials (through: CD34, CD45, CD90, CD105, CD146, CD271 markers)

Colony forming potentials of stem cells (through CFU-F analysis)

Gene expression of the osteoprogenitors (through PCR analysis)

Other baseline parameters will be noted to detect potential confounders: sex, smoking, current diets, age and body weight.

Study parameters will be compared between patients and also to the existing literature.

## Study description

### Background summary

Bone marrow cells (BMC) are rich of mesenchymal stem cells (MSC). These MSCs do have clinical potential in orthopaedics because they give rise to the cells that form mesenchymal tissues like bone and cartilage and they can be easily obtained and concentrated from bone marrow. Only little evidence is available of its content and the constancy of it among different patients, though research suggest a correlation between amount of progenitor cells and healing potentials of bone marrow aspirate at the affected area.

## **Study objective**

To quantify the MSC population of concentrated bone marrow aspirate and examine their differential potentials and the variation among patients and examine similarities and differences with the current literature.

## **Study design**

Non-invasive observational pilot study.

Bone marrow aspirate will be collected of 10 patients who suffer from a bonedefect wherefor they need a autologous cancellous bone graft of the anterior iliac crest (under general anesthesia).

If these patients meet all established criteria, they will be informed about the research and sign the informed consent form if they want to participate.

During the surgery when bone graft is obtained, we use this route to aspirate 30cc bone marrow. The surgical procedure will continue directly after this. The local researcher will perform the other procedures and then transport the aspirate to the laboratory where the analysis will be performed. There will be no follow-up of the patients.

Composition will be examined and results will be noted and compared to the existing literature and mutually between patients.

## **Study burden and risks**

This non-therapeutic research is of minor/negligible burden for the patient.

Because the osteogenic quality of bone marrow aspirates and its consistency between patients is barely studied before, this can give us a great amount of new and usefull information for future stem cell therapies in orthopedic surgery, like non-union and fracture healing or prevention of osteoarthritis.

The risk to the patient can be considered minimal and the benefits of knowing more about the basic qualities of bone marrow aspirates in orthopaedics would greatly benefit its potentials and value in clinical orthopaedic population.

## **Contacts**

### **Public**

Academisch Medisch Centrum

Meibergdreef 9

Amsterdam 1105 AZ

NL

### **Scientific**

Academisch Medisch Centrum

Meibergdreef 9  
Amsterdam 1105 AZ  
NL

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

Patients

- in need of an autologous bone graft harvested of the (anterior or posterior) iliac crest for orthopaedic reason;
- understand study proposal and sign informed consent;
- > 18 years old

### Exclusion criteria

Subjects:

- participating in other studies
- suffering from an autoimmune disease
- suffering from an infection
- suffering from a malignancy
- receiving or received chemotherapy / other bone marrow suppression medicine < 1 year ago
- suffering or suffered from a hematopoietic disease < 1 year ago
- an other known malignancy

## Study design

## Design

**Study type:** Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Other

## Recruitment

NL

Recruitment status: Will not start

Enrollment: 10

Type: Anticipated

## Ethics review

Approved WMO

Date: 07-04-2014

Application type: First submission

Review commission: METC Amsterdam UMC

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

**Register**

CCMO

**ID**

NL47846.018.14